Clinical trials: Opioid-Induced Disorders
Access to Primary Care
Access to Primary Care for People With Opioid Use Disorder
Background: Access to high quality primary care is essential for health, particularly for vulnerable populations. Research indicates, however, that people with opioid use disorder (OUD), are less likely than others to have a…
- Trial name
- NCT05484609
- Testing
- OUD scenario, Diabetes scenario
- Where
- Canada
- Volunteers
- 383 people, healthy volunteers welcome
- Sponsor
- Women's College Hospital
Opioid-Related Disorders, Substance-Related Disorders
Evaluation of L-alpha-acetylmethadol (LAAM) in Methadone Patients - 5
The purpose of this study is to determine the pharmacokinetics of L-alpha-acetylmethadol (LAAM) in adults transferred from methadone maintenance treatment for opiate dependence.
- Trial name
- NCT00000356
- Testing
- LAAM
- Where
- United States
- Sponsor
- National Institute on Drug Abuse (NIDA)
Substance Use Disorders, Recidivism
Preventing OUD in Justice-Involved Youth
The United States is experiencing an opioid epidemic. Sadly, opioid-related fatalities are on the rise, causing profound emotional, financial, and cultural impacts.
- Trial name
- POST (NCT04901312)
- Testing
- Adolescent Community Reinforcement Approach, Assertive Continuing Care, Trauma Affect Regulation Guide for Education and Therapy
- Where
- United States
- Volunteers
- 215 people
- Sponsor
- Seattle Children's Hospital
Opioid Addiction, Opioid Abuse, Continuous Use
Healthy Adult Male Facial Skin Surface Lipid Pheromone p.o. to Treat Opioid Addiction
Healthy adult human male facial skin surface lipid liquid pheromone given by mouth to opioid addicts cures them without any withdrawal symptoms whatsoever 250mg on chewing gum vehicle by mouth.
- Conditions
- Opioid Addiction, Opioid Abuse, Continuous Use, Opioid Use, Opioid-Related Disorders
- Trial name
- NCT03394911
- Testing
- 250mg healthy adult male facial skin surface lipid liquid pheromone
- Volunteers
- 500 people
- Sponsor
- Bubba Nicholson
Neonatal Abstinence Syndrome, Neonatal Opiate Withdrawal Syndrome
Buprenorphine Pharmacometric Open Label Research Study of Drug Exposure
Neonatal withdrawal syndrome is a series of signs and symptoms in infants exposed to opioids in utero. Buprenorphine has demonstrated a 40% reduction in length of pharmacologic treatment compared to oral morphine.
- Trial name
- B-PHORE (NCT03608696)
- Testing
- Buprenorphine
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Thomas Jefferson University
Neonatal Abstinence Syndrome
The Alberta Neonatal Abstinence Syndrome Mother-Baby Care ImprovEmeNT Program
Neonatal Abstinence Syndrome (NAS), is a common and costly problem in Alberta that affects approximately 250 babies per year exposed to drugs during pregnancy. Unfortunately, this has become more common in the last 10 years.
- Trial name
- NASCENT (NCT05226624)
- Testing
- Rooming-in care, Baseline standard of care
- Where
- Canada
- Volunteers
- 240 people
- Sponsor
- University of Alberta
Medication Abuse, Harm Reduction
Evaluation of Clinical Decision Support in Opioid Tapering
The 2022 Center for Disease Control and Prevention (CDC) clinical practice guideline for prescribing opioids for pain recommends that when tapering a patient's opioid dose, doses should be decreased at a slow rate to reduce the…
- Conditions
- Medication Abuse, Harm Reduction, Opioid Use Disorder, Opioid Prescribing
- Trial name
- NCT06527079
- Testing
- Observational study without a prospective intervention
- Volunteers
- 200,000 people
- Sponsor
- University of Colorado, Denver
Opioid Withdrawal (Disorder), Opioid Use Disorder
A Pharmacokinetic, Safety, and Tolerability Study of LUCEMYRA in the Treatment of Opioid Withdrawal Management in Adolescent Subjects
The goal of this clinical study is to evaluate the pharmacokinetic (PK), safety, and tolerability of LUCEMYRA in adolescents age ≥12 to <18 years old abruptly discontinuing opioid use.
- Trial name
- NCT06711640
- Testing
- LUCEMYRA (lofexidine) tablets
- Where
- United States
- Sponsor
- USWM, LLC (dba US WorldMeds)
Pain, Nausea
Optimal Dose of Prophylactic Naloxone in Reducing Opioid-Induced Side Effects in Children/Adolescents
This is an investigator initiated dose finding study designed to determine the optimal dose of naloxone to prevent or minimize the most common side effects induced by opioids, namely itching, nausea, and vomiting.
- Conditions
- Pain, Nausea, Pruritus
- Trial name
- NCT00330343
- Testing
- naloxone
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Johns Hopkins University
Neonatal Opioid Withdrawal Syndrome, Neonatal Abstinence Syndrome
Neurostimulation to Improve NOWS Outcomes
The objective of this study is to determine if tAN therapy can reduce the median number of days of oral morphine administered to an infant after start of treatment.
- Trial name
- SPROUT (NCT05129020)
- Testing
- Sparrow Fledging Therapy System
- Where
- 3 sites in United States
- Volunteers
- 52 people
- Sponsor
- Spark Biomedical, Inc.
Heroin Dependence, Morphine Dependence
Buprenorphine/Naloxone Versus Clonidine for Inpatient Opiate Detoxification - 1
The purpose of this study is to assess buprenorphine/naloxone versus clonidine for inpatient opiate detoxification.
- Conditions
- Heroin Dependence, Morphine Dependence, Substance Withdrawal Syndrome
- Trial name
- NCT00032955
- Testing
- Buprenorphine/naloxone
- Where
- 6 sites in United States
- Volunteers
- 163 people
- Sponsor
- University of California, Los Angeles
Opioid-Induced Respiratory Depression, Postoperative Complications (Cardiopulmonary)
Pupillometry in Identifying Risk of Postoperative Opioid-induced Respiratory Depression in Children Undergoing Tonsillectomy
This study will evaluate whether quantitative pupillometry measurements can be used to identify children at risk for postoperative opioid-induced respiratory depression (OIRD) following tonsillectomy.
- Conditions
- Opioid-Induced Respiratory Depression, Postoperative Complications (Cardiopulmonary), Respiratory Complications Due to Anesthesia
- Trial name
- NCT07573150
- Testing
- Infrared Pupillometry
- Where
- 2 sites in United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- NeurOptics Inc
Opioid Use, Traumatic Injury
Opioid Use After Traumatic Injury in Adolescents
Currently, 1 in 8 adolescents continue to receive prescription opioids a year or more after injury. By longitudinally surveying patients, we can identify risk factors and pathways to nonmedical opioid use.
- Conditions
- Opioid Use, Traumatic Injury, Adolescent Behavior, Substance Abuse Disorder
- Trial name
- NCT03628846
- Where
- United States
- Volunteers
- 123 people, healthy volunteers welcome
- Sponsor
- Indiana University
Opioid-Related Disorders, Opiate Addiction
Study to Validate Coded Medical Terms Used to Identify Opioid-Related Overdose in Databases Used for PMR Study 1B
The purpose of this study is to determine reliability of codes and data from electronic medical records to predict and measure overdose and death in patients prescribed opioid analgesics.
- Conditions
- Opioid-Related Disorders, Opiate Addiction, Narcotic Abuse, Drug Abuse
- Trial name
- NCT02667197
- Testing
- Algorithm to determine overdose from opioid abuse
- Volunteers
- 2,701 people
- Sponsor
- Member Companies of the Opioid PMR Consortium
Transversus Abdominis Plane (TAP) Block, Wound Infiltration
Ultrasound-guided Transversus Abdominis Plane Block Versus Local Wound Infiltration (TAP_WI)
The goal of this clinical trial is to learn if transversus abdominis plane (TAP) block will reduce the cumulative opioid consumption compared to local wound infiltration (WI).
- Conditions
- Transversus Abdominis Plane (TAP) Block, Wound Infiltration, Pain Score (VAS), Opioid Analgesia
- Trial name
- TAP (NCT06627946)
- Testing
- TAP group
- Where
- Bhutan
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Ministry of Health, Bhutan
Opioid-related Disorders, Opioid Addiction
Surveillance Monitoring of Opioid Abuse in Poison and Drug Treatment Centers
To conduct surveillance for abuse, misuse, overdose, addiction, and death and to evaluate if the REMS meets its surveillance goals, and if it does not, to modify it appropriately based on the metrics.
- Conditions
- Opioid-related Disorders, Opioid Addiction, Narcotic Abuse, Drug Abuse
- Trial name
- NCT02871232
- Testing
- Researched Abuse, Diversion and Addiction-Related Surveillance (RADARS) System of post-marketing surveillance of prescription medication abuse, misuse, and diversion
- Volunteers
- 26,500 people
- Sponsor
- ER/LA Opioid REMS Program Companies (RPC)
Substance Withdrawal Syndrome, Critical Illness
Opioid Withdrawal Symptoms in Critically Ill Patients
Most critically ill patients encounter pain and distress from acute illness, medical procedures and devices as well as routine care in the intensive care units (ICU).
- Trial name
- NCT03374722
- Testing
- Opioids
- Where
- Thailand
- Volunteers
- 55 people
- Sponsor
- Mahidol University
Opioid-Related Disorders, Substance-Related Disorders
Effects of Combined Alcohol and Nitrous Oxide Intake - 15
The purpose of this study is to determine the effects of combined alcohol and nitrous oxide intake on mood, psychomotor performance, and the pain response in healthy volunteers.
- Trial name
- NCT00000263
- Testing
- 30% Nitrous oxide, 0.25 g/Kg ethanol, 0.5 g/KG ethanol
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- University of Chicago
Neonatal Abstinence Syndrome
Buprenorphine Dose Adjustments and Gestational Age
In this retrospective cohort study, we plan to examine the relationship between buprenorphine dose adjustments, gestational age, urine buprenorphine levels and the rate of neonatal abstinence syndrome in opioid-maintained…
- Trial name
- NCT03028883
- Testing
- Dose adjustments
- Volunteers
- 40 people
- Sponsor
- St. Louis University
Pruritis
Nalbuphine for the Treatment of Opioid Induced Pruritus in Children
Itching is a frequent and disturbing side effect of the use of pain medication such as morphine. In the post-operative period, it can be more distressing to pediatric patients than their pain.
- Trial name
- NCT00323154
- Testing
- Nalbuphine
- Where
- Canada
- Volunteers
- 134 people
- Sponsor
- University of British Columbia